메뉴 건너뛰기




Volumn 3, Issue 7, 2017, Pages 529-541

Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy

Author keywords

antiangiogenic therapy; HIF; hypoxia; targeted therapy; topoisomerase inhibitors; tumor angiogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAMPTOTHECIN; HYPOXIA INDUCIBLE FACTOR; IRINOTECAN; NANOPARTICLE; PAZOPANIB; SUNITINIB; TOPOTECAN; ANTISENSE OLIGONUCLEOTIDE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; EZN 2968; NANOCONJUGATE; OLIGONUCLEOTIDE; TOP1 PROTEIN, HUMAN;

EID: 85019388346     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2017.05.002     Document Type: Review
Times cited : (84)

References (107)
  • 1
    • 77951698149 scopus 로고    scopus 로고
    • Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling
    • Rey, S., Semenza, G.L., Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc. Res. 86 (2010), 236–242.
    • (2010) Cardiovasc. Res. , vol.86 , pp. 236-242
    • Rey, S.1    Semenza, G.L.2
  • 2
    • 0028929803 scopus 로고
    • Angiogenesis in cancer, vascular, rheumatoid and other disease
    • Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995), 27–30.
    • (1995) Nat. Med. , vol.1 , pp. 27-30
    • Folkman, J.1
  • 3
    • 79957534572 scopus 로고    scopus 로고
    • Targeting hypoxia in cancer therapy
    • Wilson, W.R., Hay, M.P., Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11 (2011), 393–410.
    • (2011) Nat. Rev. Cancer , vol.11 , pp. 393-410
    • Wilson, W.R.1    Hay, M.P.2
  • 4
    • 77954836067 scopus 로고    scopus 로고
    • The tumor microenvironment in non-small-cell lung cancer
    • Graves, E.E., et al. The tumor microenvironment in non-small-cell lung cancer. Semin. Radiat. Oncol. 20 (2010), 156–163.
    • (2010) Semin. Radiat. Oncol. , vol.20 , pp. 156-163
    • Graves, E.E.1
  • 5
    • 84929358929 scopus 로고    scopus 로고
    • Combined effects of pericytes in the tumor microenvironment
    • Ribeiro, A.L., Okamoto, O.K., Combined effects of pericytes in the tumor microenvironment. Stem Cells Int., 2015, 2015, 868475.
    • (2015) Stem Cells Int. , vol.2015 , pp. 868475
    • Ribeiro, A.L.1    Okamoto, O.K.2
  • 6
    • 84992459052 scopus 로고    scopus 로고
    • Molecular targeting of hypoxia in radiotherapy
    • Rey, S., et al. Molecular targeting of hypoxia in radiotherapy. Adv. Drug Deliv. Rev. 109 (2017), 45–62.
    • (2017) Adv. Drug Deliv. Rev. , vol.109 , pp. 45-62
    • Rey, S.1
  • 7
    • 85004065577 scopus 로고    scopus 로고
    • Hypoxia-inducible factors: master regulators of cancer progression
    • Schito, L., Semenza, G.L., Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer 2 (2016), 758–770.
    • (2016) Trends Cancer , vol.2 , pp. 758-770
    • Schito, L.1    Semenza, G.L.2
  • 8
    • 84954569855 scopus 로고    scopus 로고
    • Ten years of anti-vascular endothelial growth factor therapy
    • Ferrara, N., Adamis, A.P., Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 15 (2016), 385–403.
    • (2016) Nat. Rev. Drug Discov. , vol.15 , pp. 385-403
    • Ferrara, N.1    Adamis, A.P.2
  • 9
    • 85001075180 scopus 로고    scopus 로고
    • mTOR signaling confers resistance to targeted cancer drugs
    • Guri, Y., Hall, M.N., mTOR signaling confers resistance to targeted cancer drugs. Trends Cancer 2 (2016), 688–697.
    • (2016) Trends Cancer , vol.2 , pp. 688-697
    • Guri, Y.1    Hall, M.N.2
  • 10
    • 84912096468 scopus 로고    scopus 로고
    • Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia
    • Jain, R.K., Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26 (2014), 605–622.
    • (2014) Cancer Cell , vol.26 , pp. 605-622
    • Jain, R.K.1
  • 11
    • 84876993950 scopus 로고    scopus 로고
    • Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers
    • Jain, R.K., Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 31 (2013), 2205–2218.
    • (2013) J. Clin. Oncol. , vol.31 , pp. 2205-2218
    • Jain, R.K.1
  • 12
    • 84890282284 scopus 로고    scopus 로고
    • Benefits of vascular normalization are dose and time dependent: Letter
    • Huang, Y., et al. Benefits of vascular normalization are dose and time dependent: Letter. Cancer Res. 73 (2013), 7144–7146.
    • (2013) Cancer Res. , vol.73 , pp. 7144-7146
    • Huang, Y.1
  • 13
    • 84855931910 scopus 로고    scopus 로고
    • Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs
    • Van der Veldt, A.A.M., et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21 (2012), 82–91.
    • (2012) Cancer Cell , vol.21 , pp. 82-91
    • Van der Veldt, A.A.M.1
  • 14
    • 84920445585 scopus 로고    scopus 로고
    • 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment
    • Oosting, S.F., et al. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J. Nucl. Med. 56 (2015), 63–69.
    • (2015) J. Nucl. Med. , vol.56 , pp. 63-69
    • Oosting, S.F.1
  • 15
    • 84878609062 scopus 로고    scopus 로고
    • Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake
    • Arjaans, M., et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res. 73 (2013), 3347–3355.
    • (2013) Cancer Res. , vol.73 , pp. 3347-3355
    • Arjaans, M.1
  • 16
    • 84897386715 scopus 로고    scopus 로고
    • Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model
    • Heijmen, L., et al. Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. Contrast Media Mol. Imaging 9 (2014), 237–245.
    • (2014) Contrast Media Mol. Imaging , vol.9 , pp. 237-245
    • Heijmen, L.1
  • 17
    • 84877799305 scopus 로고    scopus 로고
    • Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies
    • Heskamp, S., et al. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. Int. J. Cancer 133 (2013), 307–314.
    • (2013) Int. J. Cancer , vol.133 , pp. 307-314
    • Heskamp, S.1
  • 18
    • 33645735004 scopus 로고    scopus 로고
    • Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia
    • Franco, M., et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res. 66 (2006), 3639–3648.
    • (2006) Cancer Res. , vol.66 , pp. 3639-3648
    • Franco, M.1
  • 19
    • 84989159343 scopus 로고    scopus 로고
    • Antiangiogenic therapy in oncology: current status and future directions
    • Jayson, G.C., et al. Antiangiogenic therapy in oncology: current status and future directions. Lancet 388 (2016), 518–529.
    • (2016) Lancet , vol.388 , pp. 518-529
    • Jayson, G.C.1
  • 20
    • 84991735476 scopus 로고    scopus 로고
    • Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
    • Frentzas, S., et al. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat. Med. 22 (2016), 1294–1302.
    • (2016) Nat. Med. , vol.22 , pp. 1294-1302
    • Frentzas, S.1
  • 21
    • 84992401796 scopus 로고    scopus 로고
    • Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma
    • Kuczynski, E.A., et al. Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma. J. Natl. Cancer Inst., 108, 2016, djw030.
    • (2016) J. Natl. Cancer Inst. , vol.108 , pp. djw030
    • Kuczynski, E.A.1
  • 22
    • 85015353538 scopus 로고    scopus 로고
    • Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
    • Kuczynski, E.A., Kerbel, R.S., Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma. Chin. J. Cancer, 35, 2016, 97.
    • (2016) Chin. J. Cancer , vol.35 , pp. 97
    • Kuczynski, E.A.1    Kerbel, R.S.2
  • 23
    • 85006889134 scopus 로고    scopus 로고
    • Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models
    • Bridgeman, V.L., et al. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J. Pathol. 241 (2017), 362–374.
    • (2017) J. Pathol. , vol.241 , pp. 362-374
    • Bridgeman, V.L.1
  • 24
    • 84866524036 scopus 로고    scopus 로고
    • Tumor cell vasculogenic mimicry: from controversy to therapeutic promise
    • Seftor, R.E.B., et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am. J. Pathol. 181 (2012), 1115–1125.
    • (2012) Am. J. Pathol. , vol.181 , pp. 1115-1125
    • Seftor, R.E.B.1
  • 25
    • 84961241587 scopus 로고    scopus 로고
    • The hypoxia-related signaling pathways of vasculogenic mimicry in tumor treatment
    • Li, S., et al. The hypoxia-related signaling pathways of vasculogenic mimicry in tumor treatment. Biomed. Pharmacother. 80 (2016), 127–135.
    • (2016) Biomed. Pharmacother. , vol.80 , pp. 127-135
    • Li, S.1
  • 26
    • 79953244361 scopus 로고    scopus 로고
    • Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
    • Ebos, J.M.L., Kerbel, R.S., Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8 (2011), 210–221.
    • (2011) Nat. Rev. Clin. Oncol. , vol.8 , pp. 210-221
    • Ebos, J.M.L.1    Kerbel, R.S.2
  • 27
    • 84926205960 scopus 로고    scopus 로고
    • CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer
    • Conley, S.J., et al. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res. Treat. 150 (2015), 559–567.
    • (2015) Breast Cancer Res. Treat. , vol.150 , pp. 559-567
    • Conley, S.J.1
  • 28
    • 84863422466 scopus 로고    scopus 로고
    • Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
    • Rapisarda, A., Melillo, G., Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat. Rev. Clin. Oncol. 9 (2012), 378–390.
    • (2012) Nat. Rev. Clin. Oncol. , vol.9 , pp. 378-390
    • Rapisarda, A.1    Melillo, G.2
  • 29
    • 20544437870 scopus 로고    scopus 로고
    • Overview of tumor cell chemoresistance mechanisms
    • Gatti, L., Zunino, F., Overview of tumor cell chemoresistance mechanisms. Methods Mol. Med. 111 (2005), 127–148.
    • (2005) Methods Mol. Med. , vol.111 , pp. 127-148
    • Gatti, L.1    Zunino, F.2
  • 30
    • 84872243145 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance
    • Levitzki, A., Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu. Rev. Pharmacol. Toxicol. 53 (2013), 161–185.
    • (2013) Annu. Rev. Pharmacol. Toxicol. , vol.53 , pp. 161-185
    • Levitzki, A.1
  • 31
    • 84867531311 scopus 로고    scopus 로고
    • Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma
    • Liu, L., et al. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin. Cancer Res. 18 (2012), 5662–5671.
    • (2012) Clin. Cancer Res. , vol.18 , pp. 5662-5671
    • Liu, L.1
  • 32
    • 77952671059 scopus 로고    scopus 로고
    • Multiple receptor tyrosine kinases regulate HIF-1α and HIF-2α in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors
    • Nilsson, M.B., et al. Multiple receptor tyrosine kinases regulate HIF-1α and HIF-2α in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene 29 (2010), 2938–2949.
    • (2010) Oncogene , vol.29 , pp. 2938-2949
    • Nilsson, M.B.1
  • 33
    • 84867087464 scopus 로고    scopus 로고
    • Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
    • Schito, L., et al. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E2707–E2716.
    • (2012) Proc. Natl. Acad. Sci. U. S. A. , vol.109 , pp. E2707-E2716
    • Schito, L.1
  • 34
    • 84938117930 scopus 로고    scopus 로고
    • 2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma
    • Lin, H., et al. 2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma. Tumour Biol. 37 (2016), 381–391.
    • (2016) Tumour Biol. , vol.37 , pp. 381-391
    • Lin, H.1
  • 35
    • 84991054855 scopus 로고    scopus 로고
    • Clinical pharmacokinetics and pharmacodynamics of cabozantinib
    • Lacy, S.A., et al. Clinical pharmacokinetics and pharmacodynamics of cabozantinib. Clin. Pharmacokinet. 56 (2017), 477–491.
    • (2017) Clin. Pharmacokinet. , vol.56 , pp. 477-491
    • Lacy, S.A.1
  • 36
    • 60649087564 scopus 로고    scopus 로고
    • Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
    • Ebos, J.M.L., et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 (2009), 232–239.
    • (2009) Cancer Cell , vol.15 , pp. 232-239
    • Ebos, J.M.L.1
  • 37
    • 84887456534 scopus 로고    scopus 로고
    • Role of endothelial cell metabolism in vessel sprouting
    • De Bock, K., et al. Role of endothelial cell metabolism in vessel sprouting. Cell Metab. 18 (2013), 634–647.
    • (2013) Cell Metab. , vol.18 , pp. 634-647
    • De Bock, K.1
  • 38
    • 85069238583 scopus 로고    scopus 로고
    • Endothelial cell metabolism: parallels and divergences with cancer cell metabolism
    • Verdegem, D., et al. Endothelial cell metabolism: parallels and divergences with cancer cell metabolism. Cancer Metab., 2, 2014, 19.
    • (2014) Cancer Metab. , vol.2 , pp. 19
    • Verdegem, D.1
  • 39
    • 85012011397 scopus 로고    scopus 로고
    • Understanding the intersections between metabolism and cancer biology
    • Vander Heiden, M.G., DeBerardinis, R.J., Understanding the intersections between metabolism and cancer biology. Cell 168 (2017), 657–669.
    • (2017) Cell , vol.168 , pp. 657-669
    • Vander Heiden, M.G.1    DeBerardinis, R.J.2
  • 40
    • 84989959246 scopus 로고    scopus 로고
    • Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities
    • Goveia, J., et al. Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities. EMBO Mol. Med. 8 (2016), 1134–1142.
    • (2016) EMBO Mol. Med. , vol.8 , pp. 1134-1142
    • Goveia, J.1
  • 41
    • 85013483792 scopus 로고    scopus 로고
    • Hypoxia and cellular metabolism in tumour pathophysiology
    • Parks, S.K., et al. Hypoxia and cellular metabolism in tumour pathophysiology. J. Physiol. 595 (2017), 2439–2450.
    • (2017) J. Physiol. , vol.595 , pp. 2439-2450
    • Parks, S.K.1
  • 42
    • 85016143129 scopus 로고    scopus 로고
    • The role of fatty acid β-oxidation in lymphangiogenesis
    • Wong, B.W., et al. The role of fatty acid β-oxidation in lymphangiogenesis. Nature 542 (2017), 49–54.
    • (2017) Nature , vol.542 , pp. 49-54
    • Wong, B.W.1
  • 43
    • 84975166609 scopus 로고    scopus 로고
    • Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics
    • Navarro, P., et al. Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics. Cell Rep. 15 (2016), 2705–2718.
    • (2016) Cell Rep. , vol.15 , pp. 2705-2718
    • Navarro, P.1
  • 44
    • 84965018493 scopus 로고    scopus 로고
    • HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies
    • Subhani, S., et al. HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies. Angiogenesis 19 (2016), 257–273.
    • (2016) Angiogenesis , vol.19 , pp. 257-273
    • Subhani, S.1
  • 45
    • 84872799328 scopus 로고    scopus 로고
    • Recent agents targeting HIF-1α for cancer therapy
    • Hu, Y., et al. Recent agents targeting HIF-1α for cancer therapy. J. Cell. Biochem. 114 (2013), 498–509.
    • (2013) J. Cell. Biochem. , vol.114 , pp. 498-509
    • Hu, Y.1
  • 46
    • 0024316466 scopus 로고
    • DNA topoisomerase poisons as antitumor drugs
    • Liu, L.F., DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58 (1989), 351–375.
    • (1989) Annu. Rev. Biochem. , vol.58 , pp. 351-375
    • Liu, L.F.1
  • 47
    • 0028006314 scopus 로고
    • Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy
    • Husain, I., et al. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 54 (1994), 539–546.
    • (1994) Cancer Res. , vol.54 , pp. 539-546
    • Husain, I.1
  • 48
    • 0036682284 scopus 로고    scopus 로고
    • Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway
    • Rapisarda, A., et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62 (2002), 4316–4324.
    • (2002) Cancer Res. , vol.62 , pp. 4316-4324
    • Rapisarda, A.1
  • 49
    • 70349135129 scopus 로고    scopus 로고
    • Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma
    • Merritt, W.M., et al. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol. Ther. 8 (2009), 1596–1603.
    • (2009) Cancer Biol. Ther. , vol.8 , pp. 1596-1603
    • Merritt, W.M.1
  • 50
    • 84952303328 scopus 로고    scopus 로고
    • Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
    • Di Desidero, T., et al. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. Oncotarget 6 (2015), 42396–42410.
    • (2015) Oncotarget , vol.6 , pp. 42396-42410
    • Di Desidero, T.1
  • 51
    • 85008399987 scopus 로고    scopus 로고
    • Novel ABCG2 antagonists reverse topotecan-mediated chemotherapeutic resistance in ovarian carcinoma xenografts
    • Ricci, J.W., et al. Novel ABCG2 antagonists reverse topotecan-mediated chemotherapeutic resistance in ovarian carcinoma xenografts. Mol. Cancer Ther. 15 (2016), 2853–2862.
    • (2016) Mol. Cancer Ther. , vol.15 , pp. 2853-2862
    • Ricci, J.W.1
  • 52
    • 84961205899 scopus 로고    scopus 로고
    • Hypoxia regulates ABCG2 activity through the activation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells
    • He, X., et al. Hypoxia regulates ABCG2 activity through the activation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells. Cancer. Biol. Ther. 17 (2016), 188–198.
    • (2016) Cancer. Biol. Ther. , vol.17 , pp. 188-198
    • He, X.1
  • 53
    • 79960989122 scopus 로고    scopus 로고
    • Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors
    • Kummar, S., et al. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin. Cancer Res. 17 (2011), 5123–5131.
    • (2011) Clin. Cancer Res. , vol.17 , pp. 5123-5131
    • Kummar, S.1
  • 54
    • 84873453721 scopus 로고    scopus 로고
    • Topoisomerase inhibitors in metastatic breast cancer: overview of current practice and future development
    • Vanderbeeken, M.-C., et al. Topoisomerase inhibitors in metastatic breast cancer: overview of current practice and future development. Curr. Breast Cancer Rep. 5 (2013), 31–41.
    • (2013) Curr. Breast Cancer Rep. , vol.5 , pp. 31-41
    • Vanderbeeken, M.-C.1
  • 55
    • 84879409543 scopus 로고    scopus 로고
    • A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer
    • Kümler, I., et al. A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer. Breast Cancer Res. Treat. 138 (2013), 347–358.
    • (2013) Breast Cancer Res. Treat. , vol.138 , pp. 347-358
    • Kümler, I.1
  • 56
    • 84937516442 scopus 로고    scopus 로고
    • Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function
    • Devriese, L.A., et al. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. Br. J. Clin. Pharmacol. 80 (2015), 253–266.
    • (2015) Br. J. Clin. Pharmacol. , vol.80 , pp. 253-266
    • Devriese, L.A.1
  • 57
    • 84940956193 scopus 로고    scopus 로고
    • Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity
    • Maeda, H., Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 91 (2015), 3–6.
    • (2015) Adv. Drug Deliv. Rev. , vol.91 , pp. 3-6
    • Maeda, H.1
  • 58
    • 84962711424 scopus 로고    scopus 로고
    • CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing
    • Clark, A.J., et al. CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 3850–3854.
    • (2016) Proc. Natl. Acad. Sci. U. S. A. , vol.113 , pp. 3850-3854
    • Clark, A.J.1
  • 59
    • 84883789058 scopus 로고    scopus 로고
    • Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle
    • Eliasof, S., et al. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 15127–15132.
    • (2013) Proc. Natl. Acad. Sci. U. S. A. , vol.110 , pp. 15127-15132
    • Eliasof, S.1
  • 60
    • 84862689147 scopus 로고    scopus 로고
    • Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer
    • Gaur, S., et al. Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer. Nanomedicine 8 (2012), 721–730.
    • (2012) Nanomedicine , vol.8 , pp. 721-730
    • Gaur, S.1
  • 61
    • 84982732971 scopus 로고    scopus 로고
    • Preclinical efficacy of bevacizumab with CRLX101, an investigational nanoparticle-drug conjugate, in treatment of metastatic triple-negative breast cancer
    • Pham, E., et al. Preclinical efficacy of bevacizumab with CRLX101, an investigational nanoparticle-drug conjugate, in treatment of metastatic triple-negative breast cancer. Cancer Res. 76 (2016), 4493–4503.
    • (2016) Cancer Res. , vol.76 , pp. 4493-4503
    • Pham, E.1
  • 62
    • 84923128048 scopus 로고    scopus 로고
    • Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer
    • Pham, E., et al. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin. Cancer Res. 21 (2015), 808–818.
    • (2015) Clin. Cancer Res. , vol.21 , pp. 808-818
    • Pham, E.1
  • 63
    • 84857407549 scopus 로고    scopus 로고
    • Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
    • Conley, S.J., et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 2784–2789.
    • (2012) Proc. Natl. Acad. Sci. U. S. A. , vol.109 , pp. 2784-2789
    • Conley, S.J.1
  • 64
    • 84912151114 scopus 로고    scopus 로고
    • Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer
    • Gaur, S., et al. Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer. Nanomedicine 10 (2014), 1477–1486.
    • (2014) Nanomedicine , vol.10 , pp. 1477-1486
    • Gaur, S.1
  • 65
    • 84984977897 scopus 로고    scopus 로고
    • Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial
    • Keefe, S.M., et al. Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial. Ann. Oncol. 27 (2016), 1579–1585.
    • (2016) Ann. Oncol. , vol.27 , pp. 1579-1585
    • Keefe, S.M.1
  • 66
    • 85020798998 scopus 로고    scopus 로고
    • Targeting HIF2 in clear cell renal cell carcinoma
    • Published online December 8, 2016
    • Cho, H., Kaelin, W.G., Targeting HIF2 in clear cell renal cell carcinoma. Cold Spring Harb. Symp. Quant. Biol., 2016, 10.1101/sqb.2016.81.030833 Published online December 8, 2016.
    • (2016) Cold Spring Harb. Symp. Quant. Biol.
    • Cho, H.1    Kaelin, W.G.2
  • 67
    • 85024381247 scopus 로고    scopus 로고
    • CRLX101 in Combination with Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) versus Standard of Care (SOC) (NCT02187302)
    • Anon (2014) CRLX101 in Combination with Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) versus Standard of Care (SOC) (NCT02187302), ClinicalTrials.gov.
    • (2014)
    • Anon1
  • 68
    • 80052691602 scopus 로고    scopus 로고
    • Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects
    • Sapra, P., et al. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis, 14, 2011, 245.
    • (2011) Angiogenesis , vol.14 , pp. 245
    • Sapra, P.1
  • 69
    • 84878651631 scopus 로고    scopus 로고
    • Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer
    • Patnaik, A., et al. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother. Pharmacol. 71 (2013), 1499–1506.
    • (2013) Cancer Chemother. Pharmacol. , vol.71 , pp. 1499-1506
    • Patnaik, A.1
  • 70
    • 33847421328 scopus 로고    scopus 로고
    • Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221
    • Creighton-Gutteridge, M., et al. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin. Cancer Res. 13 (2007), 1010–1018.
    • (2007) Clin. Cancer Res. , vol.13 , pp. 1010-1018
    • Creighton-Gutteridge, M.1
  • 71
    • 85024363817 scopus 로고    scopus 로고
    • Synergistic inhibition of hypoxia inducible factor-1 (HIF-1) by NSC 644221 in combination with HDAC inhibitors
    • 4785–4785
    • Creighton-Gutteridge, M., et al. Synergistic inhibition of hypoxia inducible factor-1 (HIF-1) by NSC 644221 in combination with HDAC inhibitors. Cancer Res., 67, 2007 4785–4785.
    • (2007) Cancer Res. , vol.67
    • Creighton-Gutteridge, M.1
  • 72
    • 84896032490 scopus 로고    scopus 로고
    • Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors
    • Jeong, W., et al. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors. Cancer Chemother. Pharmacol. 73 (2014), 343–348.
    • (2014) Cancer Chemother. Pharmacol. , vol.73 , pp. 343-348
    • Jeong, W.1
  • 73
    • 84923684259 scopus 로고    scopus 로고
    • PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo
    • Pan, X., et al. PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo. Int. J. Mol. Med. 35 (2015), 995–1002.
    • (2015) Int. J. Mol. Med. , vol.35 , pp. 995-1002
    • Pan, X.1
  • 74
    • 84873091765 scopus 로고    scopus 로고
    • The VHL/HIF axis in clear cell renal carcinoma
    • Shen, C., Kaelin, W.G., The VHL/HIF axis in clear cell renal carcinoma. Semin. Cancer Biol. 23 (2013), 18–25.
    • (2013) Semin. Cancer Biol. , vol.23 , pp. 18-25
    • Shen, C.1    Kaelin, W.G.2
  • 75
    • 77949890945 scopus 로고    scopus 로고
    • Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
    • Sternberg, C.N., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28 (2010), 1061–1068.
    • (2010) J. Clin. Oncol. , vol.28 , pp. 1061-1068
    • Sternberg, C.N.1
  • 76
    • 84994626953 scopus 로고    scopus 로고
    • On-target efficacy of a HIF2α antagonist in preclinical kidney cancer models
    • Cho, H., et al. On-target efficacy of a HIF2α antagonist in preclinical kidney cancer models. Nature 539 (2016), 107–111.
    • (2016) Nature , vol.539 , pp. 107-111
    • Cho, H.1
  • 77
    • 84994669316 scopus 로고    scopus 로고
    • Targeting renal cell carcinoma with a HIF-2 antagonist
    • Chen, W., et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539 (2016), 112–117.
    • (2016) Nature , vol.539 , pp. 112-117
    • Chen, W.1
  • 78
    • 77950815444 scopus 로고    scopus 로고
    • Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer
    • Hashimoto, K., et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol. Cancer Ther. 9 (2010), 996–1006.
    • (2010) Mol. Cancer Ther. , vol.9 , pp. 996-1006
    • Hashimoto, K.1
  • 79
    • 84927618369 scopus 로고    scopus 로고
    • Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib
    • Jedeszko, C., et al. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Sci. Transl. Med., 7, 2015, 282ra50.
    • (2015) Sci. Transl. Med. , vol.7 , pp. 282ra50
    • Jedeszko, C.1
  • 80
    • 77950811722 scopus 로고    scopus 로고
    • Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer
    • Merritt, W.M., et al. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol. Cancer Ther. 9 (2010), 985–995.
    • (2010) Mol. Cancer Ther. , vol.9 , pp. 985-995
    • Merritt, W.M.1
  • 81
    • 80052495441 scopus 로고    scopus 로고
    • Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor
    • Kumar, S., et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin. Cancer Res. 17 (2011), 5656–5667.
    • (2011) Clin. Cancer Res. , vol.17 , pp. 5656-5667
    • Kumar, S.1
  • 82
    • 67651166780 scopus 로고    scopus 로고
    • Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
    • Rapisarda, A., et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol. Cancer Ther. 8 (2009), 1867–1877.
    • (2009) Mol. Cancer Ther. , vol.8 , pp. 1867-1877
    • Rapisarda, A.1
  • 83
    • 84896394473 scopus 로고    scopus 로고
    • Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors
    • Jeong, W., et al. Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors. Invest. New Drugs 32 (2014), 340–346.
    • (2014) Invest. New Drugs , vol.32 , pp. 340-346
    • Jeong, W.1
  • 84
    • 84904987878 scopus 로고    scopus 로고
    • Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor
    • Mésange, P., et al. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget 5 (2014), 4709–4721.
    • (2014) Oncotarget , vol.5 , pp. 4709-4721
    • Mésange, P.1
  • 85
    • 84907974476 scopus 로고    scopus 로고
    • 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2
    • Ma, L., et al. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. Cancer Lett. 355 (2014), 96–105.
    • (2014) Cancer Lett. , vol.355 , pp. 96-105
    • Ma, L.1
  • 86
    • 84916912453 scopus 로고    scopus 로고
    • Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab
    • Falchook, G.S., et al. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget 5 (2014), 10280–10292.
    • (2014) Oncotarget , vol.5 , pp. 10280-10292
    • Falchook, G.S.1
  • 87
    • 84868207640 scopus 로고    scopus 로고
    • Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α
    • Kim, Y.-J., et al. Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α. Int. J. Cancer 132 (2013), 29–41.
    • (2013) Int. J. Cancer , vol.132 , pp. 29-41
    • Kim, Y.-J.1
  • 88
    • 84884812874 scopus 로고    scopus 로고
    • Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3
    • Nagaraju, G.P., et al. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3. Angiogenesis 16 (2013), 903–917.
    • (2013) Angiogenesis , vol.16 , pp. 903-917
    • Nagaraju, G.P.1
  • 89
    • 79957440961 scopus 로고    scopus 로고
    • Molecular evolution of the metazoan PHD-HIF oxygen-sensing system
    • Rytkönen, K.T., et al. Molecular evolution of the metazoan PHD-HIF oxygen-sensing system. Mol. Biol. Evol. 28 (2011), 1913–1926.
    • (2011) Mol. Biol. Evol. , vol.28 , pp. 1913-1926
    • Rytkönen, K.T.1
  • 90
    • 84883501150 scopus 로고    scopus 로고
    • HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
    • Semenza, G.L., HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. 123 (2013), 3664–3671.
    • (2013) J. Clin. Invest. , vol.123 , pp. 3664-3671
    • Semenza, G.L.1
  • 91
    • 59649112848 scopus 로고    scopus 로고
    • Regulation of angiogenesis by oxygen and metabolism
    • Fraisl, P., et al. Regulation of angiogenesis by oxygen and metabolism. Dev. Cell 16 (2009), 167–179.
    • (2009) Dev. Cell , vol.16 , pp. 167-179
    • Fraisl, P.1
  • 92
    • 79956328903 scopus 로고    scopus 로고
    • Molecular mechanisms and clinical applications of angiogenesis
    • Carmeliet, P., Jain, R.K., Molecular mechanisms and clinical applications of angiogenesis. Nature 473 (2011), 298–307.
    • (2011) Nature , vol.473 , pp. 298-307
    • Carmeliet, P.1    Jain, R.K.2
  • 93
    • 60549092506 scopus 로고    scopus 로고
    • Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells
    • Lee, K., et al. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 2353–2358.
    • (2009) Proc. Natl. Acad. Sci. U. S. A. , vol.106 , pp. 2353-2358
    • Lee, K.1
  • 94
    • 79955962513 scopus 로고    scopus 로고
    • Metabolic reprogramming by HIF-1 promotes the survival of bone marrow-derived angiogenic cells in ischemic tissue
    • Rey, S., et al. Metabolic reprogramming by HIF-1 promotes the survival of bone marrow-derived angiogenic cells in ischemic tissue. Blood 117 (2011), 4988–4998.
    • (2011) Blood , vol.117 , pp. 4988-4998
    • Rey, S.1
  • 95
    • 84991696421 scopus 로고    scopus 로고
    • The impact of hypoxia on tumor-associated macrophages
    • Henze, A.-T., Mazzone, M., The impact of hypoxia on tumor-associated macrophages. J. Clin. Invest. 126 (2016), 3672–3679.
    • (2016) J. Clin. Invest. , vol.126 , pp. 3672-3679
    • Henze, A.-T.1    Mazzone, M.2
  • 96
    • 84946074699 scopus 로고    scopus 로고
    • Hypoxia: a key player in antitumor immune response
    • Noman, M.Z., et al. Hypoxia: a key player in antitumor immune response. Am. J. Physiol. Cell Physiol. 309 (2015), C569–C579.
    • (2015) Am. J. Physiol. Cell Physiol. , vol.309 , pp. C569-C579
    • Noman, M.Z.1
  • 97
    • 84911958406 scopus 로고    scopus 로고
    • Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment
    • Kumar, V., Gabrilovich, D.I., Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology 143 (2014), 512–519.
    • (2014) Immunology , vol.143 , pp. 512-519
    • Kumar, V.1    Gabrilovich, D.I.2
  • 98
    • 84859700702 scopus 로고    scopus 로고
    • Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes
    • Skuli, N., et al. Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes. J. Clin. Invest. 122 (2012), 1427–1443.
    • (2012) J. Clin. Invest. , vol.122 , pp. 1427-1443
    • Skuli, N.1
  • 99
    • 0034032882 scopus 로고    scopus 로고
    • Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
    • Browder, T., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60 (2000), 1878–1886.
    • (2000) Cancer Res. , vol.60 , pp. 1878-1886
    • Browder, T.1
  • 100
    • 0034087691 scopus 로고    scopus 로고
    • Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
    • Klement, G., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105 (2000), R15–R24.
    • (2000) J. Clin. Invest. , vol.105 , pp. R15-R24
    • Klement, G.1
  • 101
    • 84929514070 scopus 로고    scopus 로고
    • Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
    • Simkens, L.H.J., et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 385 (2015), 1843–1852.
    • (2015) Lancet , vol.385 , pp. 1843-1852
    • Simkens, L.H.J.1
  • 102
    • 84962068598 scopus 로고    scopus 로고
    • Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V
    • Colleoni, M., et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V. J. Clin. Oncol. 34 (2016), 927–935.
    • (2016) J. Clin. Oncol. , vol.34 , pp. 927-935
    • Colleoni, M.1
  • 103
    • 0024468481 scopus 로고
    • DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA
    • Bodley, A., et al. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res. 49 (1989), 5969–5978.
    • (1989) Cancer Res. , vol.49 , pp. 5969-5978
    • Bodley, A.1
  • 104
    • 70449580319 scopus 로고    scopus 로고
    • Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
    • Lee, K., et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 17910–17915.
    • (2009) Proc. Natl. Acad. Sci. U. S. A. , vol.106 , pp. 17910-17915
    • Lee, K.1
  • 105
    • 58149374576 scopus 로고    scopus 로고
    • Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth
    • Zhang, H., et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 19579–19586.
    • (2008) Proc. Natl. Acad. Sci. U. S. A. , vol.105 , pp. 19579-19586
    • Zhang, H.1
  • 106
    • 33745714060 scopus 로고    scopus 로고
    • Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A
    • Bielawski, K., et al. Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol. Pharm. Bull. 29 (2006), 1493–1497.
    • (2006) Biol. Pharm. Bull. , vol.29 , pp. 1493-1497
    • Bielawski, K.1
  • 107
    • 84860389759 scopus 로고    scopus 로고
    • HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs
    • Zhang, H., et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 31 (2012), 1757–1770.
    • (2012) Oncogene , vol.31 , pp. 1757-1770
    • Zhang, H.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.